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Neurodegenerative disorders show an increasing prevalence in a number of highly developed countries. Often,
these diseases require life-long treatment mostly with drugs which are costly and mostly accompanied by more or
less serious side-effects. Their heterogeneous manifestation, severity and outcome pose the need for individualised
treatment options. There is an intensive search for new strategies not only for treating but also for preventing these
diseases. Green tea and green tea extracts seem to be such a promising and safe alternative. However, data
regarding the beneficial effects and possible underlying mechanism, specifically in clinical trials, are rare and rather
controversial or non-conclusive. This review outlines the existing evidence from preclinical studies (cell and tissue
cultures and animal models) and clinical trials regarding preventive and therapeutic effects of epigallcatechin-3
-gallate in neurodegenerative diseases and considers antioxidative vs. pro-oxidative properties of the tea catechin
important for dosage recommendations.
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Introduction
Neurodegenerative disorders show an increasing preva-
lence in a number of highly developed countries partly
attributable to the still increasing life expectancy in these
countries but also other still not clearly identified and
characterised causal factors. Depending on the disease,
sensory, motor, cognitive and autonomic functions might
be affected differently. Once diagnosed, neurodegenerative
diseases often require life-long treatment, mostly with
drugs which are costly and mostly accompanied by more
or less serious side-effects. Governments and healthcare
providers have to face the emerging health burden of
neurodegenerative diseases. Therefore, there is an inten-
sive search for new strategies not only for treating but also* Correspondence: anja.maehler@charite.de
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reproduction in any medium, provided the orfor preventing these diseases. At the time of diagnosis,
when neurodegeneration has already become evident in
terms of symptoms, neurodegenerative cascades are al-
ready initiated and neuro-axonal degeneration cannot be
reversed with neuroprotective treatments [1]. Green tea
and green tea extracts (GTEs) seem to be a promising and
safe alternative for targeted prevention and individualised
treatment of neurological diseases. However, data regar-
ding beneficial effects and possible underlying mechanism,
specifically in clinical trials, are rare and rather controver-
sial or non-conclusive.
The pathogenesis of these diseases includes a number
of different processes such as oxidative stress, inflamma-
tion, or simply neuronal dysfunction due to neuronal
degeneration.
Neuronal tissue is more prone to oxidative damage
than other tissues because of (1) its high content of un-
saturated fatty acids that are sensitive targets for free
radical attack leading to peroxidation, (2) the brain’s
high oxygen consumption (20% of total) despite its re-
latively small (2% of human body) weight, (3) its lowLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in certain brain regions, and (5) high ascorbate level [2].
Although ascorbate serves an important role as scaven-
ger of free radicals in the human body [3], it can gener-
ate free radicals in the presence of Fe3+ and Cu2+ [4].
Tea is the most widely consumed beverage after water.
Green tea preparation precludes the oxidation of leaf
polyphenols which are thought to contribute to the
health-promoting effects. Tea polyphenols, known as
catechins, usually account for 30% to 42% of the dry
weight of the solids in brewed green tea. The four major
catechins (flavan-3-ols) are (−)–epigallocatechin-3-gallate
(EGCG), (−)-epigallocatechin (EGC), (−)-epicatechin-3-
gallate (ECG), and (−)epicatechin (EC). EGCG represents
the most abundant one of tea catechins (50% to 80% of
total catechins) [5-7]. These four catechins act as potent
antioxidants via direct scavenging of reactive oxygen and
nitrogen species (ROS and RNS), induction of defence
enzymes and binding and chelating of divalent metals,
such as copper and iron [8].
This review provides information for both basic
scientists and clinician scientists in order to encourage
translational approaches that address the issues dis-
cussed. Undertaking efforts to facilitate translational
research with respect to predictive, preventive and per-
sonalised medicine in neurodegenerative diseases was
recommended recently [1]. The review should meet
both: (1) outlining the existing evidence from preclinical
studies (cell and tissue cultures and animal models) and
clinical trials regarding preventive and therapeutic
effects of EGCG in neurodegenerative diseases (Table 1,
Figure 1) and (2) considering antioxidative vs. pro-
oxidative properties of EGCG important for dosage re-
commendations. The most important neurodegenerative
disorders will be covered.
EGCG: bioavailability and possible therapeutic targets
There is only limited data on the bioavailability of EGCG
in the brain, an important prerequisite for its neuro-
protective effects. A single, very high oral EGCG dose
(500 mg/kg body weight) to rats yielded EGCG con-
centrations of 12.3 nmol/mL in plasma and 0.5 nmol/g
in brain (measured by CL-HPLC) [55]. A single adminis-
tration of [3H] EGCG into the stomach of mice leads to
significant amounts of radioactivity in the brain -
thought to consist of EGCG itself and its metabolites in
free and protein-bound forms. A second administration
6 h later increased brain’s radioactivity above the level
measured after the first dose. This finding suggests that
EGCG obviously accumulates in the brain when given
repeatedly [56]. However, after drinking 250 ml green
tea by six human subjects, HPLC-MS analysis revealed
that flavan-3-ol methyl-glucuronide and sulfate meta-
bolites appeared in the bloodstream but did not passthrough the blood-cerebrospinal fluid barrier [57]. The
discrepancy between animal and human data might ori-
ginate from (1) the very high dose of EGCG applied in
the animal model versus the single, rather small dose
contained in one cup of tea, (2) the time point (2 h after
drinking) chosen for the lumbar puncture in the clinical
study, and (3) an apparently more rapid catechin metab-
olism in humans. Catechins and epicatechin pass the
blood brain barrier as shown by in vivo microdialysis of
rat hippocampus following intravenous application of
these basic monomer units of the flavanols [58].
Once in the brain, EGCG can influence numerous
processes. Possible underlying mechanisms derived from
in vitro and in vivo studies have been reviewed by
Mandel et al. [59]. Briefly, EGCG acts as a powerful
hydrogen-donating radical scavenger of ROS and RNS
and chelates divalent transition metal ions (Cu2+,
Zn2+ and Fe2+), thereby preventing the Fe2+-induced
formation of free radicals in vitro. Among 12 polyphe-
nolic compounds, EGCG most potently inhibited Fe2+-
mediated DNA damage and iron ascorbate-promoted
lipid peroxidation of brain mitochondrial membranes. In
vivo, EGCG increased expression and activity of antioxi-
dant enzymes, such as glutathione peroxidase, glutathi-
one reductase, superoxide dismutase (SOD) and catalase
but inhibits pro-oxidative ones, such as monoamine oxi-
dase (MAO)-B and nitric oxide synthase (NOS) [59].
ROS and RNS are well recognised for being both dele-
terious and beneficial. Overproduction of ROS results in
oxidative stress that damages membrane lipids, proteins
and DNA. In contrast, beneficial effects occurring at
low/moderate concentrations of ROS/RNS involve anti-
infective processes, various cellular signalling pathways
and induction of a mitogenic response [60]. ROS are
by-products of cellular, mainly mitochondrial, oxidative
metabolism. They are formed by enzymes that reduce
oxygen, such as MAO, xanthine oxidase, nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases and
NOS. The ‘primary’ oxygen-derived ROS is the super-
oxide anion radical (O2
·−) capable of further reactions
with other molecules to generate ‘secondary’ ROS, such
as hydrogen peroxide (H2O2), hydroxyl radical, and sing-
let oxygen [61,62] or RNS by reacting with nitric oxide
(NO·) to peroxynitrite anion (ONOO−). Within the
brain, NO is produced by cell type-specific NO syn-
xthases, i.e. neuronal (nNOS), endothelial (eNOS) and
inducible (iNOS) - the latter being specific for glial cells.
NO is essential for controlling cerebral blood flow and
neurotransmission and is involved in synaptic plasticity,
modulation of neuroendocrine functions, memory for-
mation and behavioural activity. However, NO does not
only exert protective effects in the central nervous sys-
tem (CNS) but also mediates tissue damage [63] because
of its reaction with O2
·−-yielding OONO− [64], an ion
Table 1 Effects of epigallocatechin-3-gallate
Neurological
disease
Preclinical studies Epidemiological and clinical studies
Multiple sclerosis Inflammation, proliferation and TNF-.alpha;
secretion of T cells ↓ in EAE mice [9]
Effects on T2 lesions in brain MRI in RRMS?
(NCT00525668)
Combination with glatiramer acetate: cell death ↓ and
neuronal outgrowth ↑ in primary neurons, disease severity ↓
in EAE mice [10]
Effects on brain atrophy in progressive forms?
(NCT00799890)
Th1 and Th17 ↓, Treg ↑ in EAE mice [11] Metabolic effects in MS patients? (NCT01417312)
Alzheimer’s disease Aβ-induced death of hippocampal cells ↓ [12] Effects on the course of AD in 50 early stage patients?
(NCT00951834)
α-secretase activity in Alzheimer transgenic mice ↑ [13]
Recovery of Aβ-induced memory dysfunction in mice [14]
Protection of microglia cells from Aβ-induced ↑ iNOS expression
and NO production [15]
Direct conversion of fibrillar species into benign protein
aggregates [16]
Parkinson’s disease Lipopolysaccharide-induced microglial activation ↓ [17] Inverse relation of tea drinking and PD in Chinese [18],
Western Washington [19], Finish [20], and Israelian [21]
cohortsProtection of PC12 cells against 6-hydroxydopamine-induced
apoptosis [22]
Attenuation of MPP+-induced ROS production in PC12 cells [23] Safe and efficient in de novo PD patients? (NCT00461942)
Protection against striatal dopamine depletion and neuronal loss
in MPTP mice [24]
Loss of dopaminergic neurons ↓, nNOS expression ↓ in MPTP
mice [25]
No behavioural improvements in 6-hydroxydopamine-lesioned
rats [26]
Attenuation of increased iNOS expression in MPTP mice [27]
Inhibition of levodopa methylation by catechol-O-methyltransferase
[28]
Huntington’s disease Inhibition of huntingtin protein aggregation in yeast and fly
models of HD [29]
Efficient (changes in cognitive decline) and tolerable
(1,200 mg/day for 12 months) in HD patients?
(NCT01357681)
Memory impairment ↓ in 3-NP-treated rats, glutathione level of
neuronal cells ↑ [30]
Duchenne muscular
dystrophy
Elongator digitorum longus muscle necrosis ↓ in mdx mice [31] Safe and tolerable in DMD boys? (NCT01183767)
Hind limb muscle necrosis ↓, muscle force and fatigue resistance
↑ in mdx mice [32]
Creatine kinase and oxidative stress ↓, improved histology, utrophin
↑ in mdx mice [33]
Glutathione synthesis ↑ in muscle cells cultured from mdx mice
[34]
Muscle aerobic metabolism ↑ in combination with endurance
training in mdx mice [35]
Muscle pathology in regenerating fibres ↓ in mdx mice [36]
Amyotrophic lateral
sclerosis
Delayed symptom onset, prolonged life span, attenuated death
signals in ALS mice [37]
Protection of motor neurons, microglial activation ↓ in ALS mice
[38]
Protection of motor neurons against THA-induced toxicity in rat
spinal cord explants [39]
Cerebral ischaemia Ischaemia-reperfusion brain injury↓ in gerbils [40-42], rats [43-51]
and mice [52,53]
≥3 Cups of tea/day decrease the risk of stroke [54]
↓ decreased, ↑ increased.
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Figure 1 Neurological conditions positively affected by epigallocatechin-3-gallate.
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teins [62]. The hydroxyl and trihydroxyl (gallate) groups
of EGCG appear important for scavenging physiologic-
ally relevant ROS/RNS (Figure 2) [65].
Ferric ion (Fe2+) is an essential cofactor for many
proteins involved in neuronal function. However, in-
creasing evidence suggests that Fe2+ accumulation in the
brain is pathologically relevant in CNS disorders. During
ageing, total Fe2+ concentration increases in some brain
regions that are involved in the pathogenesis of degen-
erative diseases, such as Alzheimer’s, Parkinson’s and
Huntington’s disease. This Fe2+ accumulation obviously
fosters the production of ROS [66], namely the highly
reactive OH·, which attacks a large number of functional
groups of the biomolecules in neurons. By chelatingFigure 2 Proposed neuroprotective mechanisms of epigallocatechin-3redox-active transition metal ions, the gallate groups of
EGCG are thought to inhibit the Fenton-like-reaction
mechanism [62]. Thus, the formation of highly reactive
hydroxyl radicals (OH·) is inhibited. Consequently, po-
lyunsaturated fatty acids in, for example, mitochon-
drial membranes are protected from lipid peroxidation
(Figure 2).
To maintain normal cell physiology, enzymatic anti-
oxidant mechanisms counteract ROS formation. Key
players within these mechanisms are SOD, catalase and
glutathione peroxidase, as well as enzymes involved in
the recycling of oxidised glutathione, such as glutathione
reductase and glucose-6-phosphate dehydrogenase which
is a key enzyme within the pentose phosphate pathway for
generating NADPH [67]. In aged rat and adult mouse-gallate.
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dative enzymes (Figure 2) [24,68]. EGCG also inhibited
the activity of pro-oxidative enzymes such as MAO-B and
NOS. MAO–B catalyses the oxidative deamination of
many amine neurotransmitters in the brain thereby pro-
ducing H2O2. Lin et al. first reported that EGCG supple-
mentation decreases brain MAO-B activity in adult rats
[69]. Furthermore, EGCG inhibited iNOS in lipopolysac-
charide-treated microglia cells [17] and in a mouse model
of Parkinson’s disease [27] and suppressed nNOS in the
striatum of mice [25].
There are two major subgroups of glial cells in the
brain: the macroglia (astrocytes, oligodendrocytes and
ependymal cells) and the microglia which are resident
macrophages of the brain [70]. Chronic neurodege-
nerative disorders are characterised by activation of
microglia in the affected neural pathways. Activated
microglia is a source of oxidants, prostanoids and in-
flammatory cytokines that promote neuronal damage
which in turn sustains microglial activation [71]. Thus,
agents that down-regulate microglial activation could
have favourable effects on the course of diseases accom-
panied by neurodegeneration and inflammation. There is
evidence that EGCG counteracts microglial activation in
Parkinson’s [17,72,73] and Alzheimer’s diseases [13] and
amyotrophic lateral sclerosis [38].
Therapeutic efficacy of EGCG in neurological disorders
and ageing
Multiple sclerosis
An important mechanism that underlies the major
health benefits of consuming EGCG, such as its anti-
cancer and anti-inflammatory properties, is its suppres-
sive effect on the growth of different cell types. T cells
are highly active cells and an effective T cell-mediated
immune response depends on rapid T cell expansion.
Physiological levels (0.5 to 10 μM) of EGCG inhibited
the proliferation of primary T cells from mice. This ef-
fect was mediated by inhibition of cell cycle progression
and cell division [74]. Thus, EGCG may exert an effect
on autoimmune and inflammatory diseases that involve
excessive T cell activation, such as multiple sclerosis
(MS). MS is an autoimmune inflammatory disorder of
the CNS in which focal lymphocytic infiltration not only
leads to demyelination but also axonal and neuronal
damage in both the grey and the white matter [75,76],
resulting in accrual of neurological disability during the
course of the disease and measurable atrophy of the
brain, the spinal cord and the retina [77-87]. Women
who are more frequently affected than men mainly ex-
perience disease onset during their childbearing age
[88,89]. The cause of the disease is unknown; however,
both genetic susceptibility and environmental factors,
such as vitamin D deficiency, ultraviolet B radiationexposure, smoking and Epstein-Barr virus infection, have
been shown to play a role in disease aetiopathogenesis
[90-103]. Neurological disability can occur in any func-
tional system of the CNS and manifests with impaired
vision, muscle weakness, ataxia, spasticity, gait abnor-
malities, sensory disturbances and bowel and bladder
dysfunction. A substantial number of patients also suffer
from fatigue, cognitive impairment and sleep disorders,
all of which may have a considerable negative impact on
the quality of life and vocational status [104-108]. There
is no cure for MS; injectable disease-modifying drugs
such as beta-interferons and glatiramer acetate have a
moderate impact on relapse rate and measures of disease
activity on brain magnetic resonance imaging (MRI)
with a favourable safety profile [109,110]. Newer drugs
such as natalizumab and fingolimod are more effective,
however, at a price of more severe side effects such as
progressive multifocal leukoencephalopathy, macular
oedema [111-116] or cardiac side effects [117-119]. Also
mitoxantrone, an immunosuppressive compound given
as escalation therapy in relapsing-remitting or progres-
sive MS, exhibits potentially life-threatening side effects
such as leukaemia or cardiotoxicity that limit its applica-
tion in MS patients [120-125]. Moreover, none of the
aforementioned drugs has proven neuroprotective prop-
erties. In an animal model of human MS with experi-
mental autoimmune encephalomyelitis (EAE) [126-129],
oral application of EGCG prevented and reversed the
disability and inhibited myelin-specific inflammatory res-
ponses. This effective protection against relapsing CNS
autoimmune disease resulted in a favourable long-term
clinical outcome. Furthermore, EGCG reduced axonal da-
mage and neuronal cell death by directly targeting ROS
formation. Decreased proliferation of human CD4+ T cells
incubated with EGCG could be linked to its interference
with cell cycle, NF-κB activation and protein degradation
pathway (proteasome) [9]. Combined application of EGCG
and glatiramer acetate [130-133] synergistically reduced
cell death and promoted axonal outgrowth of primary
neurons. These effects could be translated into the EAE
model in which diminished clinical disease severity was
associated with reduced CNS inflammation. Since no un-
expected adverse events occurred when the two substances
were applied together [10], their use seems promising in
clinical trials with MS patients. These findings were re-
cently confirmed and expanded by showing that EGCG
dose-dependently ameliorated clinical symptoms and de-
layed disease onset in mice with EAE, which was well
associated with reduced inflammatory infiltration and de-
myelination in the CNS. The mechanism underlying these
effects was altered regulation of CD4+ T cell subsets (Th1/
Th17 downregulation, Treg up-regulation) [11].
Meanwhile, clinical trials investigate the effects of
EGCG on (1) the number of T2 lesions in brain MRI in
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gov identifier: NCT00525668) and (2) brain atrophy
in progressive forms of MS (ClinicalTrials.gov identi-
fier: NCT00799890).
Muscle weakness and excessive muscle fatigue [134-136],
commonly experienced by MS patients, lead to a reduced
physical activity level in the course of the disease. Sufficient
energy production and/or supply are mandatory for effi-
cient muscle performance. Owing to the fact that EGCG
increases postprandial lipid oxidation in overweight/obese
male volunteers [137] and the importance of lipid oxida-
tion to fuel muscle’s energy metabolism, metabolic effects
of EGCG in MS patients are currently being investigated
(ClinicalTrials.gov identifier: NCT01417312).
Neuromyelitis optica
For a long time, neuromyelitis optica (NMO, Devic’s
syndrome) has been considered as a rare variant of MS.
However, with the detection of a highly specific serum
biomarker, an autoantibody targeting the most abundant
astrocytic water channel aquaporin-4 (AQP4), in pa-
tients with NMO but not MS or other inflammatory or
neurological diseases, it has become clear that NMO is a
disease entity distinct from MS despite a considerable
overlap in clinical presentation and paraclinical findings
[138-148]. Although commercial availability of tests for
AQP4 antibodies has facilitated differential diagnosis, a
considerable number of NMO patients are still mis-
diagnosed with MS despite emerging evidence for dif-
ferences in cerebrospinal fluid, MRI and OCT findings
[149-156]. A timely and correct diagnosis, however, is of
utmost relevance, as some of the classic immunomo-
dulatory drugs given in MS such as beta-interferons,
natalizumab and presumably also fingolimod, are ineffect-
ive or even harmful in NMO [157-165]. NMO is usually
treated with azathioprine, rituximab, mycophenolate mo-
fetil or mitoxantrone [166-171]. Very recently, the role of
T cells in the autoimmune disease process in NMO has
come into focus of research [172-174]. In addition, neu-
trophils are also apparently a major player in the pa-
thogenesis of tissue damage [175,176]. Thus, from a
pathophysiological standpoint, EGCG with its inhibitory
effect on proliferation of T cells and neutrophils [177,178]
could theoretically serve as therapeutic agent in NMO,
preferably in combination with established immunosup-
pressive drugs. However, clinical trials are lacking.
Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disease
characterised by progressive impairment of cognitive
function and loss of memory in association with wide-
spread neuronal death [179]. Neuronal loss in AD is ac-
companied by the deposition of amyloid beta protein
(Aβ) in senile plaques. ROS-induced lipid peroxidationhas been suggested to play an important role in Aβ-
mediated neurotoxicity. In cultured hippocampal neur-
onal cells, EGCG prevented Aβ-induced cell death and
lipid peroxidation through its antioxidant property. The
fundamental process of Aβ peptide formation is the pro-
teolysis of amyloid precursor protein (APP). APP pro-
teolytic products arise from the coordinated action of
α-, β-, and γ-secretases. In the amyloidogenic path-
way, Aβ peptides are produced by the initial action of
α-secretase. Conversely, the non-amyloidogenic pathway
involves events indicative of α-secretase activity. Because
intracellular APP is limited, these pathways are believed
to compete for their substrate. In cell culture, EGCG
promotes the generation of the non-amyloidogenic sol-
uble form of APP via a protein kinase C-dependent acti-
vation of α-secretase [12,179,180] and in Alzheimer
transgenic mice; it reduced cerebral amyloidosis through
promotion of α–secretase activity [13]. Furthermore, it
was found that EGCG markedly reduced secreted Aβ
levels in the conditioned medium of Chinese hamster
ovarian cells, overexpressing the ‘Swedish’ mutated APP
(CHO/ΔNL) [181] and in primary neuronal cells derived
from transgenic mice bearing the APP Swedish mutation
[13]. Consequently, compounds that alter proteolytic
cleavage of APP (by enhancing α-, or inhibiting β- and
γ-secretase activities) thereby reducing Aβ peptides are
interesting therapeutic options for AD treatment [182].
EGCG administration via drinking water recovered Aβ-
induced memory dysfunction in mice. The underlying
Aβ reduction was facilitated through increased α- and
decreased β- and γ–secretase activities (via ERK/NF-κB
pathway inhibition) respectively [14].
Oxidative stress has been suggested to play a causative
role in the pathogenesis and progression of AD [183].
Aβ accelerates neurodegeneration by activating micro-
glia, the resident macrophages in the CNS, which in turn
exert a cytotoxic effect on neurons by releasing ROS
and RNS. EGCG protected BV2 microglia cells from
Aβ-induced cytotoxicity and apoptotic cell death by sup-
pressing iNOS expression and subsequent NO produc-
tion, inhibiting intracellular peroxynitrite accumulation
and augmenting intracellular glutathione levels [15].
However, EGCG does not only influence the amyloid
formation process via modulation of cellular signal
transduction pathways and ROS production but also
directly converts fibrillar species into benign protein
aggregates [16].
To date, these experimental data have not been con-
firmed in patients with AD. However, investigations
of drug and non-drug interventions are needed. They
should be specifically designed to meet the needs of peo-
ple in the early stages of dementia [1]. An ongoing clinical
trial is investigating if EGCG positively affects the course
of AD as assessed by Alzheimer’s Disease Assessment
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patients co-medicated with acetylcholine esterase inhi-
bitors (ClinicalTrials.gov identifier: NCT00951834).
Parkinson’s disease
Parkinson’s disease (PD) is an age-related disorder cha-
racterised by progressive degeneration of dopaminergic
neurons in the substantia nigra leading to resting tremor,
rigidity, bradykinesia or slowness, gait disturbance and
postural instability [184].
Microglial activation is believed to play a pivotal role
in the selective neuronal injury associated with PD
[72,73,185-188]. In an in vitro study using dopaminergic
mesencephalic cells from rat brain, EGCG potently in-
hibited NO production and tumour necrosis factor-α
(TNF-α) release from lipopolysaccharide-activated micro-
glia. Since activated microglia is the cardinal donor of free
radicals and inflammatory factors in the brain, this in vitro
inhibition could be a reasonable explanation for EGCG-
mediated neuroprotection in vivo [17].
Pheochromocytoma (PC12) cells from rat adrenal me-
dulla, characterised by catecholamine synthesis, metab-
olism and transport [189], are used as a cellular model
of PD. A GTE [190] or EGCG (at an extreme high con-
centration of 200 μM) [22] exerted protective effects
against 6-hydroxydopamine (OHDA)-induced PC12 cell
apoptosis and death. A recent study also used PC12 cells
to investigate the effects of EGCG on 1-methyl-4-
phenyl-pyridine (MPP+)-induced cell injury. The authors
found that EGCG improved cell viability and attenuated
MPP+-induced intracellular ROS formation via the
SIRT1/PGC-1α signalling pathway [23].
Neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropy-
ridine (MPTP) produces an irreversible and severe
Parkinsonian syndrome that replicates almost all features
of PD [191]. Therefore, MPTP is used in animal models to
specifically induce dopaminergic neurodegeneration via
oxidative stress. In 2001, it was first reported that GTE
and EGCG prevented MPTP-induced loss of striatal tyro-
sine hydroxylase (TH) positive neurons, increased dopa-
mine (DA) turnover and TH activity in mice. As a result
of decreased oxidative stress, increased activities of an-
tioxidative enzymes (SOD, catalase) were attenuated by
EGCG. In mouse brain homogenates, the pro-oxidative
activity of MAO-B was inhibited [24]. NO is thought to
play an important role in mediating MPTP-induced oxida-
tive stress. Therefore, another study investigated whether
NOS underlies the protection of tea and EGCG against
MPTP-induced dopaminergic neurodegeneration in mice.
The authors attributed the prevention of dopaminergic
neuron loss, DA and DA metabolite depletion and the
preservation of striatal TH activity to the inhibition of
nNOS expression [25]. Contrary to the MPTP mouse
model of PD, in which 2 mg/kg EGCG affordedneuroprotection [24], oral pretreatment with either 1
or 2 mg/kg EGCG did not attenuate dopaminergic neuron
loss in the 6-OHDA rat model of PD. In addition, there
were no consistent improvements of behavioural mea-
sures due to EGCG treatment. This lack of neuroprotec-
tion was assumed to be due to different dose and/or
length of EGCG administration in the studies. Further-
more, the mechanisms by which MPTP and 6-OHDA
exert their neurotoxic effects are different. Unlike MPTP,
6-OHDA did not require glial cells or the dopamine trans-
porter for its activation but spontaneously auto-oxidised
to produce damaging ROS [26]. Apart from amounts used
and duration of administration, these conflicting results
could be due to the different species used. The phar-
macokinetic parameters of EGCG in the mouse are more
similar to humans in terms of EGCG plasma availability
and biotransformation than those of the rat [192], sug-
gesting that findings from mice are more relevant for
human studies. Also, the poor bioavailability of oral
EGCG in rats [193] could be a reason why similar doses
led to different results in the animal models of PD. Higher
but non-toxic doses (10 and 50 mg/kg) of EGCG reduced
neuronal death and iNOS expression in MPTP model
mice giving further evidence for its neuroprotection via
NO reduction [27]. Another proposed mechanism, by
which green tea polyphenols could protect dopaminergic
neurons against MPTP-induced injury, is by their inhibi-
tory effect on the DA-transporter which blocks the uptake
of MPTPs active metabolite (MPP+) [194].
Levodopa, a precursor in the biosynthesis of dopa-
mine, is considered to be the most effective drug to alle-
viate motor symptoms in PD patients. Computational
molecular modelling showed that EGCG is a potent,
non-competitive inhibitor but a poor substrate of
catechol-O-methyltransferase (COMT) [195]. In vitro,
EGCG inhibited human liver COMT and, therefore, the
metabolic conversion of levodopa to 3-O-methyldopa. Rats
receiving oral EGCG displayed lower 3-O-methyldopa level
in plasma and striatum [28].
Owing to the fact that PD is one of the most common
neurological diseases, there are a number of epidemio-
logical studies on the influence of environmental factors,
such as tea drinking. In 1998, a case-control study with
Chinese PD patients and controls showed that regular
tea drinking protects against PD [18]. This was con-
firmed in PD cases and controls from Washington State
in whom reduced risk for PD was related with tea con-
sumption (two cups/day) [19]. A large prospective study
in the Finish population, which usually drinks little tea,
showed a reduced risk of incident PD in subjects who
habitually drank three or more cups of tea per day [20].
However, no distinction between green and black tea
was made in the questionnaire making it difficult to
associate this finding with EGCG. Of note, Western
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is fermented and therefore contains less catechins than
green tea. The potential relevance was investigated in
the Singapore Chinese Health Study. In this prospective
cohort study, black tea drinking was inversely associated
with PD risk while green tea drinking was unrelated
[196]. A retrospective study associated drinking of more
than three cups of tea per day with a delayed onset of
motor symptoms in Israeli PD patients [21]. In this
study, no distinction was made between black and green
tea.
Whether these encouraging results from cellular and
animal models apply to humans has not been sufficiently
investigated in clinical trials yet. However, the applica-
tion of early interventions at premotor phases of PD is
desirable for patients and health care providers. Authors
of a Chinese study sought to determine whether green
tea polyphenols are effective and safe in the treatment of
de novo PD patients (who took no antiparkinsonism
drugs). Outcome measures were progression of motor
dysfunction and cognition, mood and quality of daily life
(ClinicalTrials.gov identifier: NCT00461942).
Huntington’s disease
Huntington’s disease (HD) is a dominantly inherited
neurodegenerative disorder that is caused by an unstable
expansion of a CAG repeat within the coding region of
the gene that encodes for the protein huntingtin (htt).
The mutation results in an elongated stretch of glutam-
ine near the NH2 terminus of the protein. HD symptoms
mainly occur as adult-onset HD between age 35 and 50
and comprise personality changes, generalised motor
dysfunctions, cognitive decline and neuroendocrine
disturbances [197,198].
Growing evidence suggests that the misfolding and ag-
gregation of htt is central to HD pathogenesis. The
screening of a library of natural compounds identified
EGCG and related polyphenols as potent inhibitors of
mutant htt exon 1 protein aggregation in vitro. Add-
itionally, EGCG modulated misfolding as well as the as-
sembly of oligomers in cell-free assays and reduced both
toxicity and aggregate formation in yeast and fly models
of HD [29].
3-Nitropropionic acid (3-NP), a fungal-derived neuro-
toxin that irreversibly inhibits succinate dehydrogenase,
is a well-known model to study the pathogenesis of HD.
Memory disturbances in rats caused by 3-NP treatment
were attenuated by chronic EGCG treatment. Striatal,
cortical and hippocampal glutathione levels of the rats
were significantly reduced by 3-NP treatment that was
reversed by chronic EGCG treatment. These effects were
attributed to NOS inhibition as evidenced by the ap-
plication of NO modulators (L-arginine and L-NG-
nitroarginine methyl ester) [30].A multicenter trial evaluating the efficiency and toler-
ability of EGCG in HD patients is currently ongoing.
Primary outcome measures are changes of cognitive
functions (as measured by UHDRS-Cognition composite
score of Stroop test, verbal fluency and Symbol Digit
Modalities Test) after 12 months maximal daily intake
of 1,200 mg EGCG compared to baseline intake
(ClinicalTrials.gov identifier: NCT01357681).
Duchenne muscular dystrophy
Another disease, in which the generation of ROS seems
to play an important pathogenic role, is Duchenne
muscular dystrophy (DMD) [199-201]. DMD is a severe
X-linked congenital disorder characterised by progres-
sive muscle wasting caused by the absence of the struc-
tural protein dystrophin. The pathogenesis of DMD is
frequently studied in the dystrophic mdx mouse model.
Dietary GTE supplementation preferentially protected
the elongator digitorum longus muscle rather than the
soleus muscle of mdx mice from necrosis [31]. Histo-
logical examination of leg muscles and functional recor-
dings of the triceps surae muscle contraction showed
that GTE and EGCG protected the hindlimb muscle of
dystrophic mice from massive necrosis and greatly
improved muscle force and resistance to fatigue [32].
Subcutaneous EGCG injections into the backs of mdx
mice starting immediately after birth (1) reduced the ac-
tivity of serum creatine kinase to almost normal levels,
(2) decreased oxidative stress indicated by the number
of lipofuscine granules in muscle fibres, (3) improved
the histology of both the fast-contracting diaphragm
muscle and the slow-contracting soleus, (4) increased
the mean time for the maximum tetanic force to fall by
a half (T1/2max) in mdx soleus muscles, and (5) in-
creased the amount of utrophin (partially compensating
for the lack of dystrophin) formed in mdx diaphragm
muscle [33]. A study on cultured muscle cells from mdx
dystrophic mice showed that green tea polyphenols and
EGCG offer both immediate antioxidant effects and
long-term prevention by stimulating glutathione synthe-
sis and protect against H2O2 toxicity [34]. The above
mentioned findings were recently extended to study dif-
ferent administration routes and dosages of EGCG to
find the most effective for limiting the onset of dys-
trophic lesions in both the same strain of mdx mice and
assessment methods. Oral administration of 180 mg/kg
EGCG daily in the diet for 5 weeks most effectively
reduced muscular dystrophy [202].
Endurance training (i.e. voluntary wheel running) and
0.5% GTE in the diet synergistically improved skeletal
and cardiac muscle aerobic metabolism and serum anti-
oxidant capacity and decreased lipid peroxidation and
cardiac hypertrophy in young mdx mice [35]. Prena-
tal and early dietary intervention with GTE decreased
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NF-κB activity in regenerating fibres of mdx mice [36].
In light of this considerable body of evidence, clinical
studies in DMD patients should be performed. One re-
gistered multicenter, prospective, double blind, placebo-
controlled randomised pilot study is investigating safety
and tolerance of EGCG in boys with muscular dys-
trophy of the Duchenne type (ClinicalTrials.gov iden-
tifier: NCT01183767).
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodege-
nerative disorder in which degeneration of upper and
lower motor neurons leads to progressive muscle weak-
ness and atrophy [203,204]. In recent years, non-motor
involvement has been increasingly reported in ALS
[205-212]; a clinical, pathological and genetic continuum
with frontotemporal dementia has been acknowledged
[213,214]. Moreover, it became evident that inflamma-
tory mechanisms, including microglial activation, con-
tribute not only to neuronal cell death but may also
promote neuronal survival [210,215-218]. Drugs targe-
ting inflammatory pathways showed beneficial effects on
survival in transgenic ALS mouse models [219]. The first
in vivo study on EGCG’s effects on ALS was performed
on ALS model (SOD1-G93A) mice. Oral EGCG treat-
ment (>2.9 μg/g body weight) significantly delayed
symptom onset, prolonged life span, preserved survival
signals and attenuated death signals [37]. The disease
onset delaying and survival prolonging effects of oral
EGCG treatment in ALS mice were confirmed by an-
other study. EGCG protected the motor neurons and
reduced microglia activation and associated iNOS ex-
pression, such as NF-κB and caspase-3 [38]. Another
widely used model to study ALS employs threohydroxy-
aspartate (THA), an inhibitor of glutamate transport, to
induce motor neuron death in cultured rat spinal cord
explants. In this model, EGCG protected motor neurons
against THA-induced toxicity, which was accompanied
by regulation of glutamate levels in the synaptic cleft,
and decreased tissue levels of lipid peroxides [39].
Cerebral ischaemia
Stroke is the second most common cause of death and
major cause of disability worldwide [220]. Temporary or
permanent reduction of blood flow deprives the brain of
oxygen and glucose which causes structural damage dur-
ing ischaemia and reperfusion [43,221]. Neuronal cell
death is delayed for several days after ischaemic insult
and is restricted to sensitive areas of the brain, such as
the hippocampus and the striatum [52]. Possible neu-
roprotective effects of EGCG on cerebral ischaemia have
been studied extensively in animal models. Adminis-
tration of GTE/EGCG in ischaemia-reperfusion braininjury decreased the extent of neuronal injury in experi-
mental models of stroke in gerbils [40-42], rats [43-51]
and mice [52,53].
Proposed protective actions of GTE/EGCG are (1)
increase of nNOS and eNOS but decrease of iNOS ex-
pression [43,47,49], (2) inhibition of matrix metallopro-
teinase-9 activity (which decreases degradation of matrix
components of basement membranes thereby maintai-
ning cerebral vasculature integrity) [52,53], (3) amelior-
ation of synaptic transmission [51], and (4) stimulation
of 67LR, increased generation of ROS via NADPH oxi-
dase and subsequent activation of PKCε [221]. One of
the above mentioned animal studies observed a >50% in-
crease of intracerebral haemorrhages after EGCG treat-
ment. Consequently, EGCG might not be an appropriate
intervention for the acute treatment of ischaemic stroke
[46].
A meta-analysis revealed that, regardless of their coun-
try of origin (China, Japan, Finland, The Netherlands,
Australia and USA), individuals consuming ≥3 cups of
tea per day had a 21% lower risk of stroke than those
consuming <1 cup per day [54]. To the best of our know-
ledge, there are no clinical studies addressing effects of
EGCG in human stroke.
Cognitive behaviour
Some evidence from animal and human studies indicates
a possible contribution of EGCG in the prevention of
cognitive decline. Increased release of glutamate from
CNS neurons is considered to be an indicator of main-
tenance of cognitive functions, such as learning and
memory [222,223]. On isolated nerve terminals prepared
from rat cerebral cortex, EGCG potently facilitated evo-
ked glutamate release by enhancing Ca2+ entry through
voltage-dependent Ca2+ channels, rather than any up-
stream effect on nerve terminal excitability. This release
was linked to the activation of protein kinase C (PKC)
and cytoskeleton disassembly [224].
Long-term (26 weeks) administration of green tea
catechins to rats improved their performance in radial
maze tasks and hippocampal levels of lipid peroxides.
Consequently, green tea catechins may be involved in
protecting against neuronal degenerative stress and in
the accumulation of lipid peroxides and ROS [225].
EGCG treatment of rats before and after traumatic brain
injury eliminated and/or absorbed free radicals induced
by brain injury. As a result, neuronal cell degeneration
and apoptotic cell death around the damaged area were
inhibited, and brain dysfunction was improved [226]. Fa-
tigue is an overwhelming sense of tiredness or lack of
energy, affecting both mental and physical domains. In a
rat model of load-induced chronic fatigue syndrome,
EGCG restored all behavioural and biochemical altera-
tions produced by chronic fatigue [227].
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on human cognition. A cross-sectional analysis of a self-
administered questionnaire showed that higher green tea
consumption is associated with less prevalent cogni-
tive impairment in elderly Japanese subjects [228]. In
a double-blind, placebo-controlled, balanced crossover
study, the effects of oral doses of EGCG on cerebral
blood flow in the frontal cortex during tasks that acti-
vate this brain region and cognitive performance were
investigated. A single dose of 135 mg EGCG reduced cere-
bral blood flow during task performance. However, this
was not associated with any significant modulation of ei-
ther cognitive performance or mood [229].
Ageing
Ageing is the progressive accumulation of changes over
time that is associated with, or responsible for, increas-
ing susceptibility to disease and death [230]. Oxidative
stress has been associated with both the ageing process
and the development of age-dependent tissue degenera-
tive pathologies.
The nematode Caenorhabditis elegans is a tiny round-
worm of 1 to 2 mm in length that colonises various
microbe-rich habitats, in particular, decaying plant mat-
ter. Due to its rapid lifecycle, it is one of the major
model organisms in ageing, genetic, molecular and other
biological observations [231-234]. EGCG attenuated age-
related pharyngeal contraction decline, moderately alle-
viated Aβ-induced behavioural pathologies and sustained
an increased chemotactic behaviour. However, there
were no significant increases in mean or maximal life
span due to EGCG feeding [235]. This was confirmed by
another study that found no significant longevity-
extending effects of EGCG in C. elegans under normal
culture conditions but with extension of life span by
EGCG under heat and oxidative stress [236]. In another
investigation on wild-type N2 and transgenic strains of
C. elegans, EGCG administration increased the mean
lifespan, inhibited heat shock protein expression and
decreased intracellular H2O2 levels [237].
A systematic study on the effects of EGCG on ageing
and ageing promoting factors, such as ROS accumula-
tion, mitochondrial integrity and antioxidative enzyme
activity in human fibroblasts, directly linked mitochon-
drial integrity to the efficiency of the antioxidant defence
system in the ageing process [238]. In mice in which
ageing had been induced by D–galactose, EGCG impro-
ved learning and memory functions, increased SOD and
glutathione peroxidase activities and decreased the hip-
pocampal malondialdehyde content and neuronal apop-
tosis [239].
Several neuronal systems, such as dopaminergic, cholin-
ergic and serotoninergic ones, undergo alterations during
ageing. Rats supplemented with EGCG had increasedcortical neurotransmitter levels (dopamine, acetylcholine
and serotonin) and acetylcholine esterase activity and per-
formed better in radial maze experiments when compared
to aged-matched controls [240].
Dose regimen: antioxidative versus pro-oxidative
As green tea/EGCG are becoming more and more popu-
lar due to their proposed health benefits, persons with
different pathological conditions might consume com-
mercially available supplements that contain catechin
concentrations exceeding those of tea preparations by
far. Owing to their reducing ability, antioxidant com-
pounds can activate transition metal ions (e.g. Fe3+ to
Fe2+ or Cu2+ to Cu+), making them behave as pro-oxi-
dants. It has been demonstrated that four common
dietary antioxidants (cysteine > ascorbate > EGCG >
glutathione), in the presence of copper (cupric sulfate
and cupric gluconate) and physiologically relevant levels
of H2O2, can also act as pro-oxidants by producing hy-
droxyl radicals [61]. Yoshioka et al. reported that tea
catechins advanced DNA damage and lipid peroxidation
in the presence of Cu2+. Tea catechins formed a com-
plex with Cu2+ resulting in the formation of hydroxyl
radical that, in the case of EGCG, was scavenged by the
additional gallate group [241]. Interestingly, a mixture of
the four tea catechins (Polyphenon 100) and individual
tea catechins differently modulated human cytochrome
P450 1A expression. The underlying mechanisms of
increased effectiveness of green tea and a catechin mix-
ture compared to single catechins were not elucidated in
this study [242].
Under in vitro conditions, catechins exerted antioxi-
dant and antiapoptotic properties at low concentrations
(1 to 50 μM), whereas at higher concentrations (100 to
500 μM) the reverse was observed [243]. It was de-
monstrated that GTE and EGCG inhibit cell growth and
induce cell death at concentrations of 10 to 20 μM. In
murine macrophage and human leukemic cell lines,
EGCG increased H2O2-induced oxidative stress and
DNA damage. The oxidant activity of EGCG exceeded
that of H2O2. Therefore, excessive EGCG concentrations
could induce toxic levels of ROS in vivo [244]. EGCG
dose-dependently inhibited the growth of H1299 cells in
culture and in xenograft tumours and induced ROS for-
mation both in vitro and in vivo [245].
In murine and human plasma, EGCG concentrations
up to 4 μM were reported after single doses [246-248].
However, repeated doses might lead to higher con-
centrations with possible deleterious effects. In healthy
adult mice fed with diets containing none, moderate
(0.15% and 0.3%) or high (1%) w/w EGCG for 6 weeks,
inflammatory responses were studied. While no influence
of moderate EGCG levels was observed, the high dose sig-
nificantly elevated several pro-inflammatory markers. This
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toxicity as assessed by the histological examination of se-
veral key organs [249].
For several reasons, extrapolation of these animal data
to the human situation is difficult, if not impossible. It
has to be ensured that patients treated with EGCG bene-
fit from its antioxidative effects and, at the same time,
are not harmed by pro-oxidative effects. Factors that
could lead to conflicting results between in vitro and
in vivo studies are varying degrees of responsiveness to
EGCG in patients (responder vs. non-responder), poor
bioavailability (cave:blood sample collection) that is
influenced by autoxidation (air contact) or metal ions in
food and water (calcium, magnesium and iron), exten-
sive biotransformation in the liver and variations in
serum albumin levels. To optimise EGCG bioavailability,
capsules should be stored cool and dry, taken at least 30
min before breakfast/dinner with soft water and possibly
combined with ascorbic acid, sucrose or fish oil [250].
To avoid potential side effects, clinical trials should in-
clude close attention to patients, control of liver enzymes
and regular determination of outcome measures.
Conclusions
EGCG is thought to interfere with several pathways in
numerous neurological functions in health and disease.
Despite a considerable body of evidence from cell and
animal models, there is a lack of epidemiological and
clinical studies on potential health benefits of EGCG in
patients with the neurological conditions discussed.
Within the clinical studies, the number of subjects is
mostly rather small and patients are not well phenotyped
or standardised regarding disease severity and duration.
Green tea preparations and GTEs are also not stan-
dardised. Therefore, optimum dose of EGCG for pre-
venting or treating a disease is still a matter of debate.
Before EGCG can be recommended as a targeted pre-
vention and individualised treatment to patients, the
plasma and brain bioavailability, dose-response effects,
safety, tolerability, efficacy and possible interactions with
other drugs have to be studied in more detail and in a
disease-specific manner. For a number of clinical effects
the underlying mechanisms are still unclear. Because
EGCG is acting on so many different routes (neuro-
endocrine, metabolic, defence and others), studies with
an integrated approach are strongly needed. This will be,
however, a cost-intensive and time consuming endeavour.
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